Skip Navigation

This Article
Right arrow Full Text (PDF )
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Schopohl, J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Schopohl, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Human Reproduction, Vol. 8, No. suppl_2, pp. 175-179, 1993
© 1993 European Society of Human Reproduction and Embryology

Pulsatile gonadotrophin releasing hormone versus gonadotrophin treatment of hypothalamic hypogonadism in males

Jochen Schopohl

Medizinische Klinik, Klinikum Innenstadt Ziemssenstrasse 1, D-80336 München 2, Germany

In this study, pulsatile gonadotrophin releasing hormone (GnRH) therapy and gonadotrophin therapy were compared for male patients with idiopathic hypothalamic hypogonadism. Thirty-six patients, 19 with this condition, and 17 with Kallmann's syndrome, were included in the study. Their mean age was 21.1 ± 3.0 years (±SD). They were divided into two groups of similar age, number and testicular volume. Pulsatile GnRH therapy was started with 4 µg GnRH s.c. every 2 h using a portable pump and gonadotrophin therapy with weekly i.m. injections of 3 x 2500 IU human chorionic gonadotrophin (HCG). After 8–12 weeks of HCG treatment, 150 IU human menopausal gonadotrophin (HMG) 2–4 times weekly were added and the dose of HCG reduced if necessary. Testosterone concentrations increased significantly more (P < 0.03) in the gonadotrophin group than in the GnRH group (22.5 ± 8.1 versus 16.8 ± 5.5 nmol/l). The rise in oestradiol levels was also significantly higher (P < 0.001) in the gonadotrophin group than in the GnRH group (150 ± 70 versus 88 ± 59 pmol/l). Five patients developed gynaecomastia during gonadotrophin therapy. An increased testicular volume (TV) occurred more rapidly (P < 0.001) and was significantly more pronounced (P < 0.001) after GnRH therapy ({Delta}TV = 8.1 ± 2.0 ml) than with gonadotrophins ({Delta}TV = 4.8 ± 1.8 ml). Sperm counts were performed in 14 patients given GnRH and in 17 patients given gonadotrophins. Ten patients given GnRH had positive sperm counts, ranging from 1.5 to 14 x 106 spermatozoa/ml; eight of those given gonadotrophins also developed spermatogenesis (2–26 x 106/ml). The mean time period until spermatogenesis started was significantly shorter (P < 0.02) with GnRH than with gonadotrophins (12 ± 1.6 versus 20 ± 2.3 months). These results show how endocrine and exocrine testicular function can be normalized by both forms of therapy. However, gonadotrophin therapy has more side-effects. Testicular growth is more pronounced with GnRH, and this therapy also initiates spermatogenesis more rapidly than gonadotrophin therapy.

Key words: gonadotrophin/GnRH/hypothalamic hypogonadism/male/therapy


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.